Atyr_Logo.png
aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
January 29, 2025 08:00 ET | aTyr Pharma, Inc.
Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
November 07, 2024 16:01 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
October 08, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Atyr_Logo.png
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
October 02, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Atyr_Logo.png
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update 
August 13, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
Atyr_Logo.png
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
July 22, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
June 03, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
Atyr_Logo.png
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 15, 2024 07:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
Atyr_Logo.png
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 14, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
Atyr_Logo.png
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
May 02, 2024 16:00 ET | aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update